Literature DB >> 12530286

A new approach for neurological evaluation of infants in resource-poor settings.

Leena Haataja1, Rose McGready, Ratree Arunjerdja, Julie A Simpson, Eugenio Mercuri, François Nosten, Lilly Dubowitz.   

Abstract

Research assessing the neurological development of infants in developing countries is scanty as no suitable standardised tests are available for field-use in constrained circumstances. We describe the development and application of two simple assessments. Firstly, we aimed to develop a test suitable for assessing acute neurological disturbances caused by such diverse effects as infections, drugs or toxins. This test (Shoklo Neurological Test) is aimed at infants between 9 and 36 months. The second test (Shoklo Developmental Test) is aimed not only to follow the evolution of the signs tested initially in the acute phase but also to evaluate later neurodevelopmental sequelae which might be caused by the same events. The latter test is suitable for infants aged from 3 to 12 months. Both tests can be performed easily in non-optimal conditions. The examinations were tested in a cohort of infants from a Karen refugee camp and administered in a rural setting by health workers, after appropriate training. In order to validate the tests we also applied them to a cohort of London infants. The Griffiths Developmental Scales were applied in the same infants and both the Shoklo Neurological and the Shoklo Developmental Tests showed good correlation with this standardised neurodevelopmental assessment.

Entities:  

Mesh:

Year:  2002        PMID: 12530286     DOI: 10.1179/027249302125002029

Source DB:  PubMed          Journal:  Ann Trop Paediatr        ISSN: 0272-4936


  18 in total

1.  The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.

Authors:  Rose McGready; Kasia Stepniewska; Niklas Lindegardh; Elizabeth A Ashley; Yar La; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2006-10-20       Impact factor: 2.953

2.  Assessing developmental outcomes in children from Kilifi, Kenya, following prophylaxis for seizures in cerebral malaria.

Authors:  Amina Abubakar; Fons J R Van De Vijver; Sadik Mithwani; Elizabeth Obiero; Naomi Lewa; Simon Kenga; Khamis Katana; Penny Holding
Journal:  J Health Psychol       Date:  2007-05

3.  A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.

Authors:  Rose McGready; Saw Oo Tan; Elizabeth A Ashley; Mupawjay Pimanpanarak; Jacher Viladpai-Nguen; Lucy Phaiphun; Katja Wüstefeld; Marion Barends; Natthapon Laochan; Lily Keereecharoen; Niklas Lindegardh; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  PLoS Med       Date:  2008-12-23       Impact factor: 11.069

4.  Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety.

Authors:  Sarabel G Frey; David Chelo; Mina N Kinkela; Florence Djoukoue; Felix Tietche; Christoph Hatz; Peter Weber
Journal:  Malar J       Date:  2010-10-21       Impact factor: 2.979

5.  Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia.

Authors:  Christine Manyando; Rhoda Mkandawire; Lwipa Puma; Moses Sinkala; Evans Mpabalwani; Eric Njunju; Melba Gomes; Isabela Ribeiro; Verena Walter; Mailis Virtanen; Raymond Schlienger; Marc Cousin; Miriam Chipimo; Frank M Sullivan
Journal:  Malar J       Date:  2010-09-01       Impact factor: 2.979

6.  Monitoring psychomotor development in a resource-limited setting: an evaluation of the Kilifi Developmental Inventory.

Authors:  A Abubakar; P Holding; A van Baar; C R J C Newton; F J R van de Vijver
Journal:  Ann Trop Paediatr       Date:  2008-09

7.  Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects.

Authors:  Rose McGready; Aung Pyae Phyo; Marcus J Rijken; Joel Tarning; Niklas Lindegardh; Warunee Hanpithakpon; Hla Hla Than; Nathar Hlaing; Naw Thida Zin; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

8.  Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).

Authors:  Alfred B Tiono; Halidou Tinto; Maroufou J Alao; Martin Meremikwu; Antoinette Tshefu; Bernhards Ogutu; Alphonse Ouedraogo; Moussa Lingani; Marc Cousin; Gilbert Lefèvre; Jay Prakash Jain; Stephan Duparc; Kamal Hamed
Journal:  Malar J       Date:  2015-04-15       Impact factor: 2.979

9.  Exposure to artemether-lumefantrine (Coartem) in first trimester pregnancy in an observational study in Zambia.

Authors:  Christine Manyando; Eric M Njunju; Mailis Virtanen; Kamal Hamed; Melba Gomes; Jean-Pierre Van Geertruyden
Journal:  Malar J       Date:  2015-02-14       Impact factor: 2.979

10.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.